These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 37994292)
1. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience. Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292 [TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study. Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159 [TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in New Zealand: peri-operative outcomes and service development over a decade. Lim JH; Qin RX; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S ANZ J Surg; 2024 Apr; 94(4):614-620. PubMed ID: 38240147 [TBL] [Abstract][Full Text] [Related]
4. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer. Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336 [TBL] [Abstract][Full Text] [Related]
5. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy. Sutton PA; O'Dwyer ST; Barriuso J; Aziz O; Selvasekar CR; Renehan AG; Wilson MS Surg Oncol; 2021 Sep; 38():101572. PubMed ID: 33915487 [TBL] [Abstract][Full Text] [Related]
6. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980 [TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China. Wang B; Ma R; Shi G; Fan X; Rao B; Xu H Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189 [TBL] [Abstract][Full Text] [Related]
8. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879 [TBL] [Abstract][Full Text] [Related]
9. Reclassification of Appendiceal Mucinous Neoplasms and Associated Pseudomyxoma Peritonei According to the Peritoneal Surface Oncology Group International Consensus: Clinicopathological Reflections of a Two-Center Cohort Study. Rauwerdink P; Al-Toma D; Wassenaar ECE; Raicu MG; Laclé MM; Milne AN; Kuijpers KC; Huysentruyt CJR; Poelmann FB; van Ramshorst B; Elias SG; Kranenburg O; Borel Rinkes IHM; Witkamp AJ; Wiezer MJ; van Grevenstein HMU; Boerma D Ann Surg Oncol; 2024 Dec; 31(13):8572-8584. PubMed ID: 39327362 [TBL] [Abstract][Full Text] [Related]
10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review. Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei]. Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280 [No Abstract] [Full Text] [Related]
13. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience. Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491 [TBL] [Abstract][Full Text] [Related]
14. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms. van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454 [TBL] [Abstract][Full Text] [Related]
15. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery. Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542 [TBL] [Abstract][Full Text] [Related]
16. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742 [TBL] [Abstract][Full Text] [Related]
17. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage]. Ma RQ; Xia A; Zhai XC; Chen F; Xu HB Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861 [No Abstract] [Full Text] [Related]
18. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study. Trecourt A; Bakrin N; Glehen O; Gertych W; Villeneuve L; Isaac S; Benzerdjeb N; Fontaine J; Genestie C; Dartigues P; Leroux A; Quenet F; Marchal F; Odin C; Khellaf L; Svrcek M; Thierry S; Augros M; Omar A; Devouassoux-Shisheboran M; Kepenekian V; Ann Surg Oncol; 2024 May; 31(5):3325-3338. PubMed ID: 38341381 [TBL] [Abstract][Full Text] [Related]
19. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976 [TBL] [Abstract][Full Text] [Related]
20. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Iavazzo C; Spiliotis J Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012 [No Abstract] [Full Text] [Related] [Next] [New Search]